Tao Q, Feng B
Hepatology Institute, People's Hospital, Beijing Medical University, Beijing 100044, China.
Chin Med J (Engl). 1999 Oct;112(10):942-6.
To review the achievements of the prevention and therapy of hepatitis B (HB) in China during the thirty years after the discovery of hepatitis B virus (HBV) in 1967.
Data come from an English language literature search using MEDLINE 1966-1999, especially 1982-1999, and Chinese language literature, published and unpublished, from the Chinese Health Administration.
After reviewing of the literature we select 14 articles to address our statement.
Two observers independently evaluated the quality of the data materials obtaining from these articles.
Investigation of HBV vaccine development in China was almost simultaneously with the same kind of work in the international. At least 200 million people have accepted the vaccination of HBV vaccine. The vaccination of the HBV vaccine in China has decreased the prevalence of HBV infection no matter in urban cities or in rural area. The protection against HBV infection can be maintained at least for 9-11 years.
Vaccination of HBV vaccine in China is successful and has obtained great achievements in the prevention and therapy of HB.
回顾1967年发现乙型肝炎病毒（HBV）后的三十年里中国在乙型肝炎（HB）防治方面取得的成就。
数据来自使用MEDLINE 1966 - 1999年，特别是1982 - 1999年进行的英文文献检索，以及来自中国卫生管理部门已发表和未发表的中文文献。
在对文献进行综述后，我们选择了14篇文章来阐述我们的观点。
两名观察者独立评估从这些文章中获取的数据材料的质量。
中国对HBV疫苗的研发调查几乎与国际上的同类工作同步进行。至少有2亿人接受了HBV疫苗接种。在中国，无论城市还是农村，HBV疫苗接种均降低了HBV感染的流行率。对HBV感染的保护作用至少可维持9至11年。
中国的HBV疫苗接种是成功的，在HB的防治方面取得了巨大成就。
Zotero 插件